XML 61 R51.htm IDEA: XBRL DOCUMENT v3.23.2
OTHER (INCOME)/EXPENSE, NET - Schedule Of Other Income Expense (Details) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Jun. 30, 2023
Mar. 31, 2023
Jun. 30, 2022
Mar. 31, 2022
Jun. 30, 2023
Jun. 30, 2022
Licensing Arrangements [Line Items]            
Interest expense (Note 10) $ 282   $ 313   $ 570 $ 639
Royalty and licensing income (Note 4) (340)   (287)   (703) (593)
Royalty income - divestiture (Note 4) (218)   (221)   (406) (392)
Equity investment losses (Note 9) 58   308   213 952
Integration expenses 59   124   126 229
(Gain)/Loss on debt redemption (Note 10) 0   (9)   0 266
Divestiture gains (Note 4) 0   0   0 (211)
Litigation and other settlements (a) (7)   25   (332) (12)
Investment income (95)   (27)   (197) (37)
Provision for restructuring (Note 6) 113   20   180 43
Other 32   38   20 49
Other (income)/expense, net $ (116)   $ 284   $ (529) $ 933
Nimbus Therapuetics TYK2 Inhibitor            
Licensing Arrangements [Line Items]            
Proceeds from legal settlements   $ 400   $ 40